The NT Council has been mandated by the regional council to make recommendations on the use of certain new medicines. Imfinzi, or Durvalumab, was approved earlier this fall and can be used in the treatment of adults with non-small cell lung cancer that cannot be operated but has not spread into the body.
The effect of treatment with this drug is considered moderate, but it is up to the regional and regional councils to decide whether to introduce it as a method of treatment.
Common forms of cancer
This drug is given intravenously for one hour every two weeks during the treatment period. It is estimated to cost 96,000 kronor per month for a patient.
In 2016, there were nearly 4,000 Swedes diagnosed with lung cancer. This is the sixth most common form of cancer in Sweden, but the most common cause of cancer-related deaths. This writes AstraZeneca in a press release.